Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours

Vascular endothelial growth factor (VEGF) has a key role in tumour angiogenesis by stimulating endothelial cell growth, migration and survival, and increasing vessel permeability (Ferrara, 2002; Hicklin and Ellis, 2005). Targeting VEGF with bevacizumab (a recombinant humanised anti-human VEGF monoclonal antibody), plus chemotherapy, has resulted in improved outcomes in patients with metastatic colorectal, lung, and breast cancers (Hurvitz et al, 2004; Sandler et al, 2006; Miles et al, 2010). As the antitumour activity of anti-VEGF therapy has been demonstrated, opportunities exist to further optimise these therapies to deliver further efficacy improvements.

Aflibercept (VEGF Trap) is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of human IgG1 (Holash et al, 2002). Aflibercept has broad affinity for all ligands that bind to these receptors, including isoforms of VEGF-A, VEGF-B, and placental growth factors (Holash et al, 2002; Verheul et al, 2003). In preclinical models, aflibercept demonstrated antitumour effects and antiangiogenic activity as a single agent and enhanced activity in combination with chemotherapy, including cisplatin, taxanes, and gemcitabine (Holash et al, 2002; Byrne et al, 2003; Huang et al, 2003; Fukasawa and Korc, 2004; Verheul et al, 2007; Leujeune et al, 2008; Lal et al, 2010; Lassoued et al, 2011).

A phase I study demonstrated the safety and activity of single-agent aflibercept in patients with haematologic malignancies or solid tumours (Lockhart et al, 2010). In a phase I, dose-escalation, sequential cohort study in patients with advanced solid tumours (Isambert et al, 2011), aflibercept 6 mg kg⁻¹ with docetaxel 75 mg m⁻² every 3 weeks was established as the recommended phase II trial dose (RP2D). In the second cohort from this study, reported here, the safety and tolerability of aflibercept plus platinum-based doublet chemotherapy, specifically docetaxel and cisplatin, was investigated.

MATERIALS AND METHODS

Eligibility

Patients aged ≥18 years were included if they had a histologically or cytologically confirmed solid malignancy that was metastatic or unrespectable or for which no standard conventional curative therapy existed, but for which treatment with the combination of docetaxel plus cisplatin was considered appropriate. Other main inclusion criteria were Eastern Cooperative Oncology Group performance status ≤2, adequate haematologic, hepatic and renal function, and resolution of any toxicity (except alopecia) from other anticancer treatments. Key exclusion criteria were squamous...
cell lung carcinoma; brain metastases; cumulative radiotherapy to >25% of the total bone marrow; chemotherapy, hormonal therapy, radiotherapy or surgery during the previous 3 weeks; immunotherapy or cytokine therapy within the previous 6 weeks; or uncontrolled hypertension. All patients gave written informed consent. The study (EudraCT number: 2005-001984-77) was approved by the local ethics committees and conducted according to the Declaration of Helsinki.

Study design and treatment

This was a two centre, phase I, dose-escalation, sequential cohort study. In the dose-escalation phase of the cohort reported here, patients received aflibercept (sanofi-aventis and Regeneron Pharmaceuticals Inc., 2011) by intravenous (IV) infusion over 1 h on day 1 at a starting dose of 4 mg kg⁻¹, with enrolment into the next dose levels (5 and 6 mg kg⁻¹) based on dose-limiting toxicity (DLT) observations during the first cycle (i.e., 3-week period). Dose-escalation to the subsequent dose level was made if no DLT was seen in a cohort of three patients. If DLT was observed in one patient, the cohort was expanded by at least three patients.

Study objectives

Primary objectives were to evaluate DLTs during the first cycle and determine the RP2D of aflibercept in combination with docetaxel and cisplatin. Secondary objectives were to assess safety, preliminary antitumour activity, pharmacokinetics (PKs), and immunogenicity during the entire study period.

Safety and efficacy assessments

Safety was assessed based on adverse events (AEs) (collected until 60 days after the end of study treatment), laboratory data, electrocardiograms, physical examinations, and the presence of aflibercept antibodies. Toxicities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Haematologic DLTs were grade 3/4 neutropenia complicated by fever ≥38.5°C or infection, grade 4 neutropenia for ≥7 days, grade 4 thrombocytopenia, or grade 3 thrombocytopenia with haemorrhage. Nonhaematologic DLTs were grade 3/4 nonhaematologic toxicities except fatigue, anorexia, nausea, vomiting, diarrhoea, serum alkaline phosphatase increase, or grade 3 events that were considered by the investigator and sponsor to be not clinically relevant or unrelated to study treatment. Nonhaematologic DLTs also included blood pressure ≥150/100 mm Hg (or ≥180/90 mm Hg in patients with prior history of systolic hypertension) despite 4 weeks’ medical management; urine protein >3.5 g per 24 h that did not recover to <2.0 g per 24 h within 2 weeks; and symptomatic arterial thromboembolic events. Safety evaluations were performed on all patients exposed to at least one dose of aflibercept (safety-evaluable population).

Tumour response was assessed according to RECIST criteria version 1.0 using magnetic resonance imaging (MRI) or computed tomography (CT) on day 21 (±4 days) of every even-numbered cycle, at the end of the study treatment, if disease progression was suspected or to confirm a response. Patients evaluable for antitumour activity were those who underwent baseline assessment, received at least two cycles of study treatment, and had at least one post-baseline CT or MRI scan unless early progression or death occurred.

Pharmacokinetic analyses and assessment

Pharmacokinetic analyses were performed on the safety-evaluable population. Plasma samples were obtained pretreatment, then at 1, 2, 4, 8, 24, and 48 h after the start of aflibercept infusion on days 1, 7, and 14 during cycle 1. Samples were collected before dosing for subsequent cycles and at the end of treatment. Levels of free aflibercept and VEGF-fiblercept complex (VEGF-bound aflibercept) were measured in plasma by direct enzyme-linked immunosorbent-based assay (ELISA), with a limit of quantification (LOQ) of 15.6 and 43.9 ng ml⁻¹, respectively. Concentrations of VEGF-bound aflibercept were converted into equivalents of free aflibercept taking into account molecular weights before PK analysis. Pharmacokinetic parameters of free and VEGF-bound aflibercept were assessed using non-compartmental analysis (WinNonlin Professional, version 5.2.1, PharSight, Raleigh-Durham, NC, USA). Pharmacokinetic parameters for both free and VEGF-bound aflibercept were plasma concentrations before starting infusion at each treatment cycle (Cthrough) and the maximum observed plasma concentration (Cmax).

For VEGF-bound aflibercept only, time to reach Cmax (tmax) and area under the concentration vs time curve from time 0 to tlast (time corresponding to the last plasma concentration above the LOQ) (AUC0–tlast) were measured. Additional parameters for free aflibercept only included AUC from time 0 to infinity (AUC0–∞), terminal elimination half-life (t1/2), and clearance (CL).

Plasma samples for docetaxel and total cisplatin analysis were obtained pretreatment and at various time points on cycle 1, day 1; plasma levels were measured by electrospray liquid chromatography mass spectrometry (LOQ 1.00 ng ml⁻¹) and by inductively coupled plasma mass spectrometry (LOQ 100 ng ml⁻¹). Pharmacokinetic parameters were estimated using a Bayesian estimation method for docetaxel (CL) and by non-compartmental analysis for cisplatin (AUC0–24h).

Immunogenicity

Serum samples were obtained from all treated patients, before aflibercept dosing on day 1 of each odd-numbered treatment cycle, at the end of treatment, and 3 months after the last aflibercept administration. Detection of anti-aflibercept antibodies was performed using a validated quasi-quantitative ELISA method.

RESULTS

Between 20 March 2006 and 1 February 2008, 30 patients were enrolled and treated, 16 in the dose-escalation phase and 14 in the expansion cohort (Table 1). The median age was 53.5 (range, 27–76) years and most patients had advanced breast (23.3%) or ovarian cancer (20.0%). Twenty-nine patients (96.7%) had received prior chemotherapy. Fifteen had received taxanes and one receiving 6 mg kg⁻¹ and two receiving 4 mg kg⁻¹. Ten patients had received cisplatin or carboplatin, two of whom were refractory. All patients discontinued the study treatment for the following reasons: RECIST-defined progressive disease (11 patients), clinical progressive disease (symptoms increase and general health deterioration considered by the investigator as due to progressive disease in 5 patients) and biological progression (raised tumour marker levels in 1 patient), AEs (11 patients), and planned cancer surgery (2 patients).
Table 1  Patient and tumour characteristics at baseline

|                   | Aflibercept, 4 mg kg⁻¹, n = 6 | Aflibercept, 5 mg kg⁻¹, n = 7 | Aflibercept, 6 mg kg⁻¹, n = 17 | Aflibercept, all, n = 30 |
|-------------------|-------------------------------|-------------------------------|-------------------------------|------------------------|
| Gender, female, n (%) | 6 (100.0)                    | 7 (100.0)                     | 8 (47.1)                      | 21 (70.0)              |
| Median age, years (range) | 52.5 (45–69)                 | 53.0 (39–58)                  | 57.0 (27–76)                  | 53.5 (27–76)           |
| ECOG performance status, n (%) | 0 (25.0)                     | 2 (33.3)                      | 7 (100.0)                     | 14 (82.4)              |
| Primary tumour site, n (%) | 0 (25.0)                      | 2 (33.3)                      | 7 (100.0)                     | 14 (82.4)              |
| Breast             | 3 (50.0)                      | 2 (28.6)                      | 2 (11.8)                      | 7 (23.3)               |
| Ovary              | 3 (50.0)                      | 2 (28.6)                      | 1 (5.9)                       | 6 (20.0)               |
| Colon              | 0 (0.0)                       | 1 (14.3)                      | 3 (17.6)                      | 4 (13.3)               |
| Sarcoma            | 0 (0.0)                       | 0 (0.0)                       | 4 (23.5)                      | 4 (13.3)               |
| Rectum             | 0 (0.0)                       | 0 (0.0)                       | 2 (11.8)                      | 2 (6.7)                |
| Other*             | 0 (0.0)                       | 2 (28.6)                      | 5 (29.4)                      | 7 (23.3)               |
| Median number of organs involved (range) | 2.5 (1–4)                    | 2.0 (1–6)                     | 2.0 (1–5)                     | 2.0 (1–6)             |
| Prior surgery, n (%) | 6 (100.0)                     | 7 (100.0)                     | 14 (82.4)                     | 27 (90.0)              |
| Prior radiotherapy, n (%) | 3 (50.0)                     | 3 (42.9)                      | 6 (35.3)                      | 12 (40.0)              |
| Prior chemotherapy, n (%) | 6 (100.0)                    | 7 (100.0)                     | 16 (94.1)                     | 29 (96.7)              |
| Median number of lines of prior chemotherapy (range) | 4.0 (3–4)                    | 4.0 (2–4)                     | 2.5 (1–5)                     | 4.0 (1–5)             |
| Prior taxane therapy, n (%) | 6 (100.0)                    | 4 (57.1)                      | 5 (29.4)                      | 15 (50.0)              |
| Prior platinum therapy, n (%) | 4 (66.6)                     | 4 (57.1)                      | 2 (11.8)                      | 10 (33.3)             |

Abbreviation: ECOG, Eastern Cooperative Oncology Group. *Including cancers of the cervix, oesophagus, eye, lung, other female genital organs, pancreas, and pleura. **Cisplatin or carboplatin.

Study drug exposure

Thirty patients received a total of 171 infusions of aflibercept, with a median of 5 (range, 1–13) infusions. The median relative dose intensity (RDI) for aflibercept was 0.91 with 4 mg kg⁻¹, 0.92 with 5 mg kg⁻¹, and 1.00 with 6 mg kg⁻¹ (Table 2). Median RDIs for docetaxel (0.83) and cisplatin (0.75) were lower than those for aflibercept due to high numbers of dose reductions (36.7% and 46.7% of patients, respectively) and the premature discontinuation of chemotherapy secondary to chemotherapy-related toxicity (30.0% and 50.0% of patients, respectively).

Safety evaluation

At the first aflibercept dose level of 4 mg kg⁻¹, one patient out of three experienced febrile neutropenia, considered as a DLT. Three additional patients were enrolled at this dose level, with no DLTs observed. In the aflibercept 5 mg kg⁻¹ cohort, one of the first two patients receiving aflibercept experienced febrile neutropenia. The protocol was subsequently amended to recommend primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) starting in cycle 1. It was decided not to consider febrile neutropenia as a DLT, as it was mainly due to chemotherapy and could be effectively prevented by G-CSF administration. The third patient treated at 5 mg kg⁻¹ received prophylactic G-CSF and, subsequently, four additional patients received 5 mg kg⁻¹, without experiencing DLT. Three patients received aflibercept 6 mg kg⁻¹, without experiencing DLTs. In another phase I study, combining aflibercept with docetaxel 75 mg m⁻², the RP2D of aflibercept was established at 6 mg kg⁻¹ (Isambert et al, 2011). As the addition of cisplatin did not appear to impact on tolerability, aflibercept 6 mg kg⁻¹ in combination with docetaxel 75 mg m⁻² and cisplatin 75 mg m⁻² was selected as the RP2D for the triplet combination and aflibercept dose-escalation was halted, although no DLTs were observed after the amendment. Fourteen additional patients received aflibercept 6 mg kg⁻¹ plus docetaxel and cisplatin in an expansion cohort, five of whom had DLTs: three had stomatisis, one had back pain, and one reported chest pain.

All 30 patients experienced at least one treatment-associated AE on study treatment. The 10 most common nonhaematologic AEs (all grades and across all dose groups) regardless of relationship to study medication were: asthenia/fatigue (100.0%), epistaxis (83.3%), stomatitis (76.7%), nausea (73.3%), dysphonia (70.0%), diarhoea (60.0%), vomiting (60.0%), headache (56.6%), hypertension (50.0%), and alopecia (40.0%). Treatment-emergent AEs are presented in Table 2. The most frequent grade 3/4 nonhaematologic AEs were asthenia/fatigue and stomatisis (six patients each, 20.0% each), hypertension (five patients, 16.7%) and musculoskeletal, and connective tissue pains (three patients, 10.0%). Most patients experienced haematologic toxicity, with no apparent dose effect (Table 3).

Adverse events (all grades) associated with VEGF blockade were observed at all dose levels and included epistaxis (83.3%), dysphonia (70.0%), proteinuria (53.3%), and hypertension (50.0%). High blood pressure occurred predominantly in cycles 1 or 2 and was well controlled with antihypertensive medication (mainly calcium channel blockers and diuretics). Sixteen patients experienced proteinuria, with grade 3 proteinuria and thrombotic microangiopathy reported in one patient receiving 6 mg kg⁻¹. One patient in the 4 mg kg⁻¹ group experienced grade 3/4 pulmonary embolism and one patient in the 6 mg kg⁻¹ group experienced grade 3/4 deep-vein thrombosis. Grade 3/4 intestinal perforation was reported in one patient who received aflibercept 5 mg kg⁻¹; treatment was discontinued, surgery was performed, and the patient’s general condition improved rapidly.

The main haematologic AEs were lymphopenia and anaemia (90.0% each). Grade 3/4 neutropenia was reported in all patients who received aflibercept 4 mg kg⁻¹ (who did not receive

Table 2  Median exposure, actual dose intensity, and relative dose intensity by dose level

|                   | Aflibercept, 4 mg kg⁻¹, n = 6 | Aflibercept, 5 mg kg⁻¹, n = 7 | Aflibercept, 6 mg kg⁻¹, n = 17 |
|-------------------|-------------------------------|-------------------------------|-------------------------------|
| Median number of aflibercept infusions (range) | 5 (3–8)                       | 6 (3–12)                      | 4 (1–13)                      |
| Aflibercept dose intensity (mg kg⁻¹ per week) | 1.21 (1.0–1.3)                | 1.54 (1.4–1.7)                | 1.99 (1.4–2.0)                |
| Aflibercept relative dose intensity | Median (range) | 0.91 (0.8–1.0) | 0.92 (0.8–1.0) | 1.00 (0.7–1.0) |
| Median number of docetaxel infusions (range) | 4.5 (3–6)                     | 6 (3–12)                      | 4 (1–9)                       |
| Docetaxel relative dose intensity | Median (range) | 0.81 (0.5–1.0) | 0.81 (0.6–1.0) | 0.85 (0.4–1.0) |
| Median number of cisplatin infusions (range) | 4.5 (2–6)                     | 6 (3–9)                       | 4 (1–8)                       |
| Cisplatin relative dose intensity | Median (range) | 0.70 (0.5–1.0) | 0.83 (0.5–1.0) | 0.77 (0.4–1.0) |

Abbreviation: VEGF, vascular endothelial growth factor; Aflibercept, Novartis; Docetaxel, Bristol-Myers Squibb; Cisplatin, GlaxoSmithKline; AE, adverse event; DLT, dose-limiting toxicity; HP, high blood pressure; G-CSF, granulocyte colony-stimulating factor; RDI, relative dose intensity.
Table 3 Relevant nonhaematologic and haematologic treatment-emergent adverse events occurring with an incidence of 10% or more

| AE, n (%)                      | Aflibercept, 4 mg kg\(^{-1}\), n = 6 | Aflibercept, 5 mg kg\(^{-1}\), n = 7 | Aflibercept, 6 mg kg\(^{-1}\), n = 17 |
|-------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                               | Grade 3/4                             | All grade                             | Grade 3/4                             | All grade                             | Grade 3/4                             | All grade                             |
| Any AE                        | 6 (100.0)                             | 6 (100.0)                             | 5 (71.4)                              | 7 (100.0)                             | 16 (94.1)                             | 17 (100.0)                             |
| Nonhaematologic               |                                       |                                       |                                       |                                       |                                       |                                       |
| Asthenia/fatigue              | 1                                     | 6 (100)                               | 0                                     | 7 (100)                               | 5 (29.4)                              | 17 (100)                               |
| Epistaxis                     | 0                                     | 6 (100.0)                             | 0                                     | 7 (100.0)                             | 0                                     | 12 (70.6)                              |
| Stomatitis                    | 0                                     | 5 (83.3)                               | 2 (28.6)                              | 6 (85.7)                               | 4 (23.5)                              | 12 (70.6)                              |
| Nausea                        | 1 (16.7)                              | 5 (83.3)                               | 0                                     | 6 (85.7)                               | 1 (5.9)                               | 11 (64.7)                              |
| Dysphoria                     | 0                                     | 4 (66.7)                               | 0                                     | 6 (85.7)                               | 0                                     | 11 (64.7)                              |
| Diarrhoea                     | 1 (16.7)                              | 5 (83.3)                               | 0                                     | 5 (71.4)                               | 0                                     | 8 (47.1)                               |
| Vomiting                      | 1 (16.7)                              | 6 (100.0)                             | 0                                     | 5 (71.4)                               | 0                                     | 7 (41.2)                               |
| Headache                      | 0                                     | 3 (50.0)                               | 0                                     | 5 (71.4)                               | 1 (5.9)                               | 9 (52.9)                               |
| Hypertension                  | 1 (16.7)                              | 4 (66.7)                               | 2 (28.6)                              | 6 (85.7)                               | 2 (11.8)                              | 5 (29.4)                               |
| Alopecia                      | 0                                     | 1 (16.7)                               | 0                                     | 4 (57.1)                               | 0                                     | 7 (41.2)                               |
| Abdominal pain                | 0                                     | 3 (50.0)                               | 0                                     | 2 (28.6)                               | 1 (5.9)                               | 5 (29.4)                               |
| Nail disorder                 | 0                                     | 1 (16.7)                               | 1 (14.3)                              | 4 (57.1)                               | 0                                     | 5 (29.4)                               |
| Haematologic                  |                                       |                                       |                                       |                                       |                                       |                                       |
| Lymphopenia                   | 4 (66.7)                              | 6 (100.0)                             | 3 (42.9)                              | 7 (100.0)                             | 5 (29.4)                              | 14 (82.4)                              |
| Anaemia                       | 1 (16.7)                              | 6 (100.0)                             | 0                                     | 7 (100.0)                             | 0                                     | 14 (82.4)                              |
| Thrombocytopenia              | 1 (16.7)                              | 5 (83.3)                               | 1 (14.3)                              | 6 (85.7)                               | 2 (11.8)                              | 12 (70.6)                              |
| Neutropenia                   | 6 (100.0)                             | 6 (100.0)                             | 3 (42.9)                              | 4 (57.1)                               | 4 (23.3)                              | 8 (47.1)                               |
| Leucopenia                    | 5 (83.3)                              | 6 (100.0)                             | 2 (28.6)                              | 3 (42.9)                               | 3 (17.6)                              | 7 (41.2)                               |
| Urinalysis                    | 0                                     | 3 (50.0)                               | 0                                     | 3 (42.9)                               | 1 (5.9)                               | 10 (58.8)                              |
| Proteinuria                   | 0                                     | 3 (50.0)                               | 0                                     | 3 (42.9)                               | 10 (58.8)                             |                                       |

Abbreviation: AE = adverse event.

Antitumour activity

In one patient, the tumour was not evaluable due to a lack of proper assessment during the study. Five patients had a partial response (PR): one at 4 mg kg\(^{-1}\) and four at 6 mg kg\(^{-1}\) (Table 4). Partial responses occurred in two patients with ovarian cancer (at 4 and 6 mg kg\(^{-1}\)) and one patient each with cancer of the breast, oesophagus, and pancreas (all receiving 6 mg kg\(^{-1}\)). The patients with breast or ovarian cancer were all pretreated and refractory to taxanes. All six patients with ovarian cancer were pretreated with platinum agents. The longest duration of response was 19.1 months in a breast cancer patient with four prior lines of chemotherapy who received 12 cycles of study treatment. Eighteen patients had stable disease (SD). Ten of these patients had SD lasting >3 months, two of whom had SD lasting >10 months.

Table 4 Antitumour activity

| AE, n (%)                      | Aflibercept, 4 mg kg\(^{-1}\), n = 6 | Aflibercept, 5 mg kg\(^{-1}\), n = 7 | Aflibercept, 6 mg kg\(^{-1}\), n = 17 |
|-------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                               | Grade 3/4                             | All grade                             | Grade 3/4                             | All grade                             | Grade 3/4                             | All grade                             |
| Best overall response, n (%)  |                                       |                                       |                                       |                                       |                                       |                                       |
| Partial response              | 1 (16.7)                              | 0                                     | 4 (23.5)                              | 5 (16.7)                              |                                       |                                       |
| Stable disease                | 4 (66.7)                              | 7 (100.0)                             | 7 (41.2)                              | 18 (60.0)                             |                                       |                                       |
| Progressive disease           | 0                                     | 6 (35.3)                              | 6 (20.0)                              |                                       |                                       |                                       |
| Not evaluable                 | 1 (16.7)                              | 0                                     | 0                                     | 1 (3.3)                               |                                       |                                       |
| Patients with stable disease  | 3 (50.0)                              | 3 (42.9)                              | 4 (23.5)                              | 10 (33.3)                             |                                       |                                       |
| for >3 months, n (%)          |                                       |                                       |                                       |                                       |                                       |                                       |

Pharmacokinetic evaluation

Plasma concentration–time profiles for free and VEGF-bound aflibercept over cycle 1 are shown in Figure 1. The PK parameters for free and VEGF-bound aflibercept at cycle 1 are summarised in Table 5. Mean exposures to free aflibercept were similar across the dose range tested with a 1.2-fold (90% confidence interval (CI), 0.91–1.5) and 0.99-fold (90% CI, 0.78–1.3) increase in \(C_{\text{max}}\) and AUC, respectively, for a 1.5-fold increase in dose. However, individual free aflibercept CL values were consistent with observations obtained in the first cohort (Isambert et al, 2011), supporting liniarity of PK in the 4–6 mg kg\(^{-1}\) dose range. Terminal half-life was around 5 days. Across the same dose range, exposures to VEGF-bound aflibercept were constant, with a 1.1-fold (90% CI, 0.80–1.4) and 1.1-fold (90% CI, 0.89–1.3) increase in \(C_{\text{max}}\) and AUC\(_{\text{gasp}}\), respectively, for a 1.5-fold increase in dose. At 4, 5, or 6 mg kg\(^{-1}\), VEGF-bound aflibercept reached a plateau by cycle 3. Under steady-state conditions, the mean free to VEGF-bound aflibercept \(Q_{\text{through}}\) ratio was higher than 1 at all doses studied (Table 6). The doublet combination of docetaxel and cisplatin did not have an impact on the PK profile of aflibercept (Lockhart et al, 2010).
Clinical Studies

602

are consistent with data for docetaxel (Bruno et al., 2010; Harvey et al., 2011), other anti-VEGF agents (Hurwitz et al., 2004; Sandler et al., 2006; Miles et al., 2010), and the combination of docetaxel and cisplatin (Fossella et al., 2003; Segawa et al., 2010; Chang et al., 2011). The incidence of the main DLT febrile neutropenia, expected with the cisplatin-docetaxel regimen (Aapro et al., 2011), was considerably reduced with the administration of prophylactic G-CSF. Adverse events associated with VEGF blockade, such as epistaxis, dysphonia, and hypertension, were frequent, but manageable, and similar to those observed with other antiangiogenic drugs or with aflibercept (Isambert et al., 2011).

Five patients experienced PRs (16.7%), four of whom received aflibercept 6 mg kg⁻¹. The patients exhibiting PRs had different primary tumour sites (ovarian (two), breast, oesophagus, and pancreas) and three had taxane-refractory tumours. In addition, 18 patients (60.0%) had SD, lasting >3 months in 10 patients. These results are consistent with the phase I study of aflibercept plus docetaxel in patients with advanced solid tumours (Isambert et al., 2011). In this study, 30 patients received aflibercept 6 mg kg⁻¹ plus docetaxel, 4 experienced PRs (13.3%), and 17 had SD (56.7%), with 12 patients (40.0%) experiencing stabilisation >3 months.

In the current study, the mean free to VEGF-bound aflibercept ratio was >1 over the 4–6 mg kg⁻¹ dose range, suggesting there was sufficient free aflibercept to be biologically active. Adding aflibercept to docetaxel plus cisplatin did not influence the PK of the individual agents. On the basis of DLTS, an acceptable safety profile, PK, and evidence of durable antitumour activity, aflibercept 6 mg kg⁻¹ with docetaxel 75 mg m⁻² and cisplatin 75 mg m⁻² every 3 weeks was selected as the RP2D.

Final results from phase III studies of aflibercept plus chemotherapy have been recently published (Van Cutsem et al., 2011). In the VELOUR study in the second-line treatment of metastatic colorectal cancer (n = 1266), aflibercept plus 5-fluorouracil, leucovorin, and irinotecan improved the primary endpoint of overall survival (HR, 0.817; P = 0.003), PFS (HR, 0.76; P = 0.00007), and overall response rate (Van Cutsem et al., 2011). In the VITAL study in the second-line treatment of NSCLC, aflibercept plus docetaxel did not meet its primary endpoint of improving overall survival compared with docetaxel plus placebo (HR, 1.01; 95% CI, 0.87–1.17) but did improve PFS (HR, 0.82; 95% CI, 0.72–0.94) and overall objective response rate (23.3% and 8.9%, respectively). Results for aflibercept plus other chemotherapy combinations are awaited from trials in several tumour types, including metastatic prostate cancer.

In conclusion, aflibercept 6 mg kg⁻¹ is the recommended dose in combination with docetaxel 75 mg m⁻² and cisplatin 75 mg m⁻² every 3 weeks (with prophylactic G-CSF), and evidence of antitumour activity in patients with advanced solid malignancies has been described. Because of the type, frequency, and severity of some AEs, this combination is not easily manageable in heavily pretreated patients, but feasible regarding the individual benefit risk ratio.

Table 5  Mean (CV %) of steady-state aflibercept individual median Cᵣₒᵤᵣ₈ value

| Dose (mg kg⁻¹) | Number of patients | Free aflibercept | VEGF-bound aflibercept | Free/bound ratio |
|---------------|--------------------|------------------|------------------------|-----------------|
| 4             | 6                  | 4.19 (84)        | 3.80 (26)              | 1.08 (83)       |
| 5             | 7                  | 7.58 (74)        | 4.14 (22)              | 1.58 (65)       |
| 6             | 15                 | 4.94 (107)       | 3.71 (28)              | 1.30 (108)      |

Abbreviations: Cᵣₒᵤᵣ₈ = concentration before dosing; CV = coefficient of variation; VEGF = vascular endothelial growth factor.

Immunogenicity

All serum samples were negative for drug-specific anti-aflibercept antibodies for all patients.

DISCUSSION

This study determined the RP2D of aflibercept when given with the standard chemotherapy doublet of docetaxel and cisplatin. Some toxicities were higher than might be expected, however, in this heavily pretreated and heterogeneous population of patients with advanced solid tumours, it was demonstrated that the AE profile was manageable and consistent with that reported in other clinical studies with aflibercept (Leighl et al., 2010; Lockhart et al., 2010; Isambert et al., 2011), other anti-VEGF agents (Hurwitz et al., 2004; Sandler et al., 2006; Miles et al., 2010), and the combination of docetaxel and cisplatin (Fossella et al., 2003; Segawa et al., 2010; Chang et al., 2011). The incidence of the main DLT febrile neutropenia, expected with the cisplatin-docetaxel regimen (Aapro et al., 2011), was considerably reduced with the administration of prophylactic G-CSF. Adverse events associated with VEGF blockade, such as epistaxis, dysphonia, and hypertension, were frequent, but manageable, and similar to those observed with other antiangiogenic drugs or with aflibercept (Isambert et al., 2011).

In conclusion, aflibercept 6 mg kg⁻¹ is the recommended dose in combination with docetaxel 75 mg m⁻² and cisplatin 75 mg m⁻² every 3 weeks (with prophylactic G-CSF), and evidence of antitumour activity in patients with advanced solid malignancies has been described. Because of the type, frequency, and severity of some AEs, this combination is not easily manageable in heavily pretreated patients, but feasible regarding the individual benefit risk ratio.

Docetaxel CL (mean ± standard deviation) was 24.3 ± 7.091 h⁻¹ m⁻² and cisplatin AUC₀₋₂₄ was 42.1 ± 8.8 h µg ml⁻¹. These values are consistent with data for docetaxel (Bruno et al., 1998; Harvey et al., 2006) and cisplatin (sanoxic-aventis internal data (data not shown)), indicating that aflibercept did not modify cisplatin and docetaxel PK.

Table 5  Mean (CV %) of steady-state aflibercept individual median Cᵣₒᵤᵣ₈ value

| Dose (mg kg⁻¹) | Number of patients | Free aflibercept | VEGF-bound aflibercept | Free/bound ratio |
|---------------|--------------------|------------------|------------------------|-----------------|
| 4             | 6                  | 4.19 (84)        | 3.80 (26)              | 1.08 (83)       |
| 5             | 7                  | 7.58 (74)        | 4.14 (22)              | 1.58 (65)       |
| 6             | 15                 | 4.94 (107)       | 3.71 (28)              | 1.30 (108)      |

Abbreviations: Cᵣₒᵤᵣ₈ = concentration before dosing; CV = coefficient of variation; VEGF = vascular endothelial growth factor.

Table 5  Mean (CV %) free and VEGF-bound aflibercept pharmacokinetic parameters at cycle 1

|               | Afibercept, 4 mg kg⁻¹ | Afibercept, 5 mg kg⁻¹ | Afibercept, 6 mg kg⁻¹ |
|---------------|-----------------------|-----------------------|-----------------------|
| Number of patients | 6                     | 7                     | 16                    |
| Cmax, µg ml⁻¹   | 93.5 (49)             | 96.4 (20)             | 106 (38)              |
| AUC₀₋C₀, µg day ml⁻¹ | 369 (35)       | 397 (20)             | 372 (32)              |
| t½, day         | 5.46 (36)             | 5.60 (26)             | 4.76 (28)             |
| CL, l per day   | 0.624 (22)            | 0.797 (16)            | 1.22 (32)             |
| VEGF-bound aflibercept |               |                       |                       |
| Number of patients | 6                     | 7                     | 17                    |
| Cmax, µg ml⁻¹   | 1.92 (19)             | 2.67 (28)             | 2.30 (42)             |
| tmax, day       | 17.5 (13.8–21.1)      | 21.2 (14.0–22.9)      | 21.0 (7.0–21.3)       |
| t½, day         | 21.0 (19.9–21.1)      | 21.2 (20.0–22.9)      | 21.1 (20.1–21.3)      |
| AUC₀₋C₀, µg day ml⁻¹ | 24.4 (13)       | 35.3 (38)             | 279 (18)              |

Abbreviations: AUC₀₋C₀ = area under the concentration vs time curve from time 0 to infinity (æ); AUC₀₋tmax = area under the concentration vs time curve from time 0 to tmax; Cmax = maximum observed plasma concentration; CL = clearance; CV = coefficient of variation; t½ = terminal elimination half-life; tmax = time corresponding to the last plasma concentration above the limit of quantification; tmax = time of maximum plasma concentration; VEGF = vascular endothelial growth factor. *Median (minimum – maximum) values. **n = 6. ***n = 13.

Figure 1  Mean free and VEGF-bound aflibercept concentration over time profiles at cycle 1. Abbreviation: VEGF = vascular endothelial growth factor.
ACKNOWLEDGEMENTS

This study was supported by sanofi-aventis in collaboration with Regeneron Pharmaceuticals. The authors received editorial support in the preparation of this manuscript provided by Cancer Communications and Consultancy Ltd, funded by sanofi-aventis. We are fully responsible for the content and editorial decisions for this manuscript.

REFERENCES

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjian-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47: 8–32

Bruno R, Hille D, Riva A, Vivier N, ten Kokkin Huijnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187–196

Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos & (2012) Cancer Research UK British Journal of Cancer (2012) license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.